Literature DB >> 2454635

Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout.

D Axelrod1, S Preston.   

Abstract

One hundred male patients who presented with acute gouty arthritis were alternately assigned to 2 treatment groups. Seventy-six patients completed the study protocol, in which each gout attack during a 1-year period was treated. For each gout episode, 36 patients received a single intramuscular injection of 40 IU of adrenocorticotropic hormone (ACTH), and 40 patients received oral indomethacin, 50 mg 4 times daily with meals, until the pain abated. The time interval until the pain was relieved, as well as any untoward effects, were recorded for each gout attack treated. Both groups were of similar age, and had similar values for intercritical serum uric acid, 24-hour urinary uric acid, and creatinine clearance (1 month after entry into the study). The mean interval (+/- SD) to relief of pain was significantly shorter for the ACTH group (3 +/- 1 hours) than for the indomethacin group (24 +/- 10 hours). No side effects were noted in the ACTH group. However, of the 40 patients receiving indomethacin, 22 had abdominal discomfort of dyspepsia, 15 had headaches, and 12 had difficulty with mentation. Single-dose parenteral ACTH appeared to be effective more rapidly and was associated with fewer side effects than oral indomethacin in the treatment of acute gout.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2454635     DOI: 10.1002/art.1780310618

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  22 in total

1.  Rheumatology: 4. Acute monoarthritis.

Authors:  J Cibere
Journal:  CMAJ       Date:  2000-05-30       Impact factor: 8.262

2.  Orthopaedic case of the month: medial knee pain in a 69-year-old man.

Authors:  Rej S Bhumbra; Monica Khanna; Brendan C Dickson; Peter C Ferguson
Journal:  Clin Orthop Relat Res       Date:  2010-10-19       Impact factor: 4.176

Review 3.  Gout in solid organ transplantation: a challenging clinical problem.

Authors:  Lisa Stamp; Martin Searle; John O'Donnell; Peter Chapman
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  Gout treatment: what is evidence-based and how do we determine and promote optimized clinical care?

Authors:  Ted R Mikuls; Kenneth G Saag
Journal:  Curr Rheumatol Rep       Date:  2005-06       Impact factor: 4.592

Review 5.  The challenges of gout management in the elderly.

Authors:  Lisa K Stamp; Sarah Jordan
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

Review 6.  Role of proopiomelanocortin-derived peptides and their receptors in the osteoarticular system: from basic to translational research.

Authors:  Markus Böhm; Susanne Grässel
Journal:  Endocr Rev       Date:  2012-06-26       Impact factor: 19.871

Review 7.  Management of acute and chronic gouty arthritis: present state-of-the-art.

Authors:  Naomi Schlesinger
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 8.  Prevention and management of gout.

Authors:  V L Star; M C Hochberg
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

9.  Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis.

Authors:  H Ralph Schumacher; Judith A Boice; David I Daikh; Saurabh Mukhopadhyay; Kerstin Malmstrom; Jennifer Ng; Guillermo A Tate; Javier Molina
Journal:  BMJ       Date:  2002-06-22

Review 10.  Systemic corticosteroids for acute gout.

Authors:  H J E M Janssens; P L B J Lucassen; F A Van de Laar; M Janssen; E H Van de Lisdonk
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.